Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

    Investigator: Siddhartha Ganguly

    Study Coordinator: Natolie Hamilton

    Status: Enrolling

    ClinicalTrials.gov Number: NCT05243797

    Phone: 713.441.4203

    Protocol Number: PRO00038933

    Description


    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.